Immunetics

company

About

Immunetics, a biotechnology company, develops immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases.

  • 51 - 100

Details

Last Funding Type
Grant
Last Funding Money Raised
$3.70M
Industries
Biotechnology,Health Diagnostics,Life Science
Founded date
Jan 1, 1987
Number Of Employee
51 - 100
Operating Status
Active

Immunetics, Inc., a biotechnology company, researches and develops immunoassay and molecular probe kits and instruments for the diagnosis of infectious diseases. Its products include Miniblotter instrument system for western blot, spoligotyping, and various multi-probe membrane assays; cell adhesion flow chamber for cell-cell interaction studies; and C6 peptide Lyme ELISA, a synthetic peptide ELISA test for Lyme disease anthrax. The company's products also include QuickELISA, a blood test for anthrax infection; and QualiCode western blot assays for diseases where diagnosis is challenging. In addition, it offers QuickELISA Anthrax-PA kit, an in vitro diagnostic test for the detection of antibodies to protective antigen of anthrax in human and animal samples; and BacTx Test for the bacterial contamination of platelets. The company sells its products through distributors in Belgium, Denmark, Norway, Finland, Sweden, France, Germany, Italy, the Netherlands, Switzerland, the United Kingdom, Canada, Honduras, Brazil, Ecuador, Venezuela, Australia, China, Korea, and Taiwan. Immunetics, Inc. was founded in 1987 and is based in Boston, Massachusetts.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$3.70M
Immunetics has raised a total of $3.70M in funding over 2 rounds. Their latest funding was raised on Sep 10, 2012 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 10, 2012 Grant $3.70M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Immunetics is funded by 1 investors. National Institutes of Health are the most recent investors.
Investor Name Lead Investor Funding Round
National Institutes of Health Grant